"kag: i have a problem with your statement that to you, the drop after the ABT deal would have been predictable because of no revenue."
Bocxman,
After looking at my statement above again, I agree that "because of no revenue" is too simplistic. Obviously, there are many other factors, such as the ones you mentioned, at play here too. I was just not at all surprised that the stock price drifted lower during the past year and that was what I would have guessed it would have done. It has been my experience with start up biotech's that investors are always more interested in "show me the money" than anything else. Fortunately for us, BOCX could be relatively close to some real money. kag.